




FIG. 1




FIG. 2

3/22




FIG. 3

4/22




FIG. 4




FIG. 5A




FIG. 5B

6/22




FIG. 6A




FIG. 6B

7/22




FIG. 7

8/22




FIG. 8A




FIG. 8B




FIG. 8C

9/22

Antitumor activity of Compound 1 in
PC3 xenograft model with qd dosing




FIG. 9

10/22




FIG. 10

11/22




FIG. 11

12/22

Antitumor Activity in PC3 Xenograft with b.i.d. Dosing




FIG. 12

13/22




FIG. 13




FIG. 14




FIG. 15




FIG. 16

17/22




FIG. 17




FIG. 18

19/22




FIG. 19

20/22




FIG. 20

21/22

Biomarker Inhibition in PC3 Xenograft Model





FIG. 21

22/22




FIG. 22